PHOTOTHERAPY AND CELLULAR TECHNOLOGIES APPLICATION IN COMPLEX VITILIGO  THERAPY. OWN EXPERIENCE

About the author:	
Tsepkolenko V.O., Karpenko K.S.	
Heading	CLINICAL OBSERVATIONS	
Type of article	Scientific Article	
Annotation	Vitiligo is a chronic acquired disorder of skin pigmentation, characterized by the 
presence of sharply limited depigmented areas of the skin as a result of the 
progressive loss of melanocytes.
The purpose of the work: increasing the effectiveness of treatment of patients with 
vitiligo by shortening the treatment period, ensuring the stability of results and 
reducing the number of complications with combined methods of treatment of a 
stable form of vitiligo with the use of cultured melanocytes and keratinocytes 
compared to methods approved by European standards and domestic orders.
Study object and methods:107 vitiligo patients aged19 to65 were under our 
observation. Depending on the method of treatment, the patients were randomly 
selected into two representative groups: the main group, which received treatment 
according to the developed method, and the comparison group, which received 
traditional treatment. When evaluating the results of treatment in examined patients
8 and16 weeks after the start of therapy, more pronounced positive dynamics were
 found in patients of the main group, whose complex therapy included melanocyte-
keratinocyte suspension(MCS) and automesoconcentrate(AMK).
Conclusions: the analysis of the results of treatment of patients with vitiligo proved 
not only good tolerance, but also high efficiency of treatment when using, along 
with traditional therapy, cellular technologies	
Tags	vitiligo treatment, melanocytes, keratinocytes, cell technologies, regenerative
 technologies, automesoconcentrate.	
Bibliography	1. Sposib kompleksnogo likuvannia stabilnogo vitiligo [Method of stable vitiligo 
complex treatment]: patent 116071 Ukraine: MPK А61N5/06, А61K 35/36, 
А61K 35/16, C12N5/02. No a2017 00467; claim. 26.12.2016; publ. 25.01.2018, 
Bul. No 2.
2. Sposib kompleksnogo likuvannia stabilnogo vitiligo [Method of stable vitiligo 
complex treatment]: patent 99068 Ukraine: MPK А61К 35/16. No u 2015 00469; 
claim. 22.01.2015; publ. 12.05.2015, Bul. No 9
3. Sposib otrimannia kriolizatu trombocitiv ludini [The method of obtaining 
human platelets cryolizate]: patent 112536 Ukraine: MPK С12М 1/02, 
А61К 35/19, А61Р 7/02. No u 2016 05254; claim. 16.05.2016; publ. 26.12.2016,
 Bul. No 24.
4. Usovetsky I. A., Sharova N. M., Korotky N. G. Sovremenniy vzgliad na 
problemy lecheniya vitiligo [Modern view on the problem of vitiligo treatment].
 Klinicheskaya dermatologiya i venerologiya. 2012;10(2):118–123.
5. Tsepkolenko V. А., Karpenko E. S. Repigmentacia koshi s ispolsovaniem 
kletochnih technologiy. Obzor literatyri [Skin repigmentation using cellular 
technologies. Literature review]. Vestnik esteticheskoi medicini. 2014;14 (3–4):
90–104.
6. Tsepkolenko V. O., Karpenko K. S. Kliniko‑gistologichni i imunohistochimichni 
zistavlennya osoblivostey urashennya shkiri u hvorich na vitiligo 
[Clinical‑histological and immunohistochemical comparisons of features of skin 
lesions in patients with vitiligo]. Art of Medicine, 2020;3(15):160–166.
7. Tsepkolenko V. O., Karpenko K. S. Metodi likyvannya vitiligo. Ogliad 
literaturi. [Methods of treatment of vitiligo. Literature review]. Dermatologia ta 
Venerologiya. 2020;1(87):57–63.
8. Rokni GR, Golpour M, Gorji AH et al. Effectiveness and safety of topical 
tacrolimus in treatment of vitiligo. J Adv Pharm Technol Res. 2017 J
an‑Mar;8(1):29–33.
9. Falabella R., Barona M. I. Update on skin repigmentation therapies in 
vitiligo. Pigment Cell & Melanoma Res. 2008;22:42–65.
10. Shen C, Gao J, Sheng Y et al. Genetic Susceptibility to Vitiligo: GWAS 
Approaches for Identifying Vitiligo Susceptibility Genes and Loci. Frontiers in 
Genetics. 2016 February, 1;7 (A. – 3):1–12.
11. Guideline on Vitiligo [Електронний ресурс] // Guideline Subcommittee 
«Vitiligo» of the European Dermatology Forum. 2014. Режим доступу до 
ресурсу: http://www.euroderm.org/edf/index.php/edf‑guidelines/category/5-guidelines‑miscellaneous?download=37: guideline-vitiligo
12. Taieb A, Alomar A, Böhm M. et al. Guidelines for the management of 
vitiligo: the European Dermatology Forum consensus. VitiligoEuropean Task 
Force (VETF); European Academy of Dermatology and Venereology (EADV); 
Union Europe´enne des Me´decins Spe´cialistes (UEMS). Br J Dermatol. 2013;
168(1):5–19.
13. Kossakowska MM, Cieścińska C, Jaszewska J, Placek WJ. Control of 
negative emotions and its implication for illness perception among psoriasis 
and vitiligo patients. J Eur Acad Dermatol Venereol. 2010 Apr;24(4):429–33.
14. Mutalik S, Shah S, Sidwadkar V, Khoja M. Efficacy of Cyclosporine After 
Autologous Noncultured Melanocyte Transplantation in Localized Stable Vitiligo –  A Pilot, Open Label, 
Comparative Study. Dermatol Surg. 2017 Nov.;43(11):1339–1347.
15. Njoo M. D., Spuls P. I., Bos J. D. et al. Nonsurgical repigmentation 
therapies in vitiligo. Meta-analysis of the literature. Archives of Dermatology. 
1998;134:1532–1540.
16. Bae JM, Jung HM, Hong BY et al. Phototherapy for Vitiligo: A Systematic 
Review and Meta‑analysis. JAMA Dermatol. 2017; Jul 1;153(7):666–674.
17. Rusfianti M., Wirohadidjodjo Widodo Y. Dermatosurgical techniques for 
repigmentation of vitiligo. International Journal of Dermatology. 2006; 45: 411–417.
18. Sawant NS, Vanjari NA, Khopkar U. Gender Differences in Depression, 
Coping, Stigma, and Quality of Life in Patients of Vitiligo. Dermatol Res Pract. 
2019;(7):1–10
19. Kota RS, Vora RV, Varma JR et al. Study on Assessment of Quality of 
Life and Depression in Patients of Vitiligo. Indian Dermatol Online J. 2019
Mar-Apr;10(2):153–157.
20. Singh RK, Lee KM, Vujkovic‑Cvijin I et al. The role of IL‑17 in vitiligo: 
A review. Autoimmunity Reviews. 2016 April;15(4):397–404.
21. Tsepkolenko V, Karpenko K. Combined treatment of stable vitiligo treatment 
using autologous cultured melanocytes and keratinocytes suspension. 28th 
Congress of the European Academy of Dermatology and Venereology, Madrid, 
Spain: 2019 (poster presentation and abstract).
22. Tsepkolenko V, Karpenko K. Combined treatment of stable vitiligo 
using cell technologies. 24th World Congress of Dermatology, Milan, Italy: 2019 
(poster presentation and abstract).
23. Tsepkolenko V, Karpenko K. Clinical-histological and immunohistochemical 
comparisons of vitiligo skin before and after a complex treatment using cell 
technologies. Aesthetic Medicine. 2023;9 (1):12–21.
24. Lotti T, Gori A, Zanieri F et al. Vitiligo: new and emerging treatments. 
Dermatol Ther. 2008 Mar‑Apr; 21(2):110–7.
25. Iannella G, Greco A, Didona D et al. Vitiligo: Pathogenesis, clinical
 variants and treatment approaches. Autoimmun Rev. 2016 Apr;15(4):335–43
	
Publication of the article	«DERMATOLOGY AND VENEREOLOGY» №1(99), 2023 year, 20-24 pages,
	
DOI	10.33743/2308-1066-2023-1-20-24